Awakening the Giant: The Next Frontier in mRNA Therapeutics We’ve seen what mRNA can do in vaccines—but that was only the beginning. In a new article published in American Pharmaceutical Review , Vernal’s CSO Christian Cobaugh, Ph.D., outlines how mRNA…
Messenger RNA has redefined what rapid looks like in drug development. Yet the very flexibility that makes mRNA attractive also makes it unforgiving—minute variations in purity, structure, or LNP encapsulation can eliminate potency or introduce safety risks. It’s never too soon to…
The remarkable success of messenger RNA-based vaccines during the COVID-19 pandemic has sparked widespread interest and enthusiasm around mRNA technology. But vaccines are just the beginning. Researchers and biotech innovators worldwide are rapidly uncovering the broader potential of mRNA to…
The Evolving Needs of Therapeutic mRNA Developers Insights on the next wave of challenges mRNA innovators face as an increasing number of therapeutics move through the pipeline. Read Article Behind the Headlines Panel Discussion Christian Cobaugh, Ph.D., Vernal Biosciences founder…
How Vernal Helped Akagera Boost Vaccine Efficacy, Cut Costs, and Speed Development Pioneering mRNA Therapies for Infectious Diseases in Cost-Sensitive Regions Founded in 2019, Akagera Medicines is advancing novel liposomal formulations of antibacterial drugs to enhance drug delivery and uptake…
Given the strides medical researchers and therapeutic developers were making, the possibility of commercializing mRNA therapeutics began looking bright about ten to fifteen years ago. However, one of the most pressing issues restricting researchers’ efforts was the lack of a…
How an mRNA-encoded antibody platform could accelerate therapies to clinic Therapeutic antibody production is traditionally complex and costly, which drives up treatment prices. However, encoding antibodies with mRNA offers a potential solution to many of these challenges, making the process…
mRNA for Antibody Manufacturing In collaboration, Charles River Lab and Vernal Biosciences released this scientific poster. Since its release, new advancements have been made and new data is available to share. Join the webinar on December 12 to dive into…
In this talk, we dive into the critical quality attributes (CQAs) of mRNA and lipid nanoparticles (LNPs) that directly impact drug efficacy and safety. You’ll gain insights into essential and cutting-edge analytical techniques and nanopore sequencing, mass spectrometry, and laser-induced…
Pioneering mRNA Therapies to Combat Hypercholesterolemia and Improve Long-Term Health Repair Biotechnologies, a preclinical biotech, is developing innovative therapies for age-related diseases such as hypercholesterolemia. Their lead asset aims to address the underlying cause of atherosclerosis, representing their ambition to…
New Leadership Reflects Commitment to Advancing mRNA Technologies and Operational Excellence, Helping Drug Developers Deliver Innovative Therapies Faster. COLCHESTER, Vt., October 31, 2024 /BUSINESS WIRE/ — Vernal Biosciences Inc., a leader in mRNA and lipid nanoparticle (LNP) development, manufacturing, and…
Nature Nanotechnology: Tissue-Specific mRNA Therapeutic Delivery Researchers have developed a combinatorial design of siloxane-incorporated LNPs to enhance tissue-specific mRNA therapeutic delivery. This article explains how this approach improves intracellular processing and stability of mRNA, showing promise for targeted treatments and…